In our study, BACEi treatment did not ameliorate the reductions of NaV1.1 and NaV1.6 levels in the parietal cortex of J20 mice (Fig. 9), providing a plausible explanation for the lack of functional improvements after BACEi treatment in this model and, possibly, also in humans with AD. Here, SCN1A is linked to Alzheimer disease.